Active	Status	Sponsor type	Region	Phase	Filter
11 Active 15 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cohen, Ezra
NCT02769520: Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck	Active, not recruiting	2	27	US	Pembrolizumab, Keytruda	Assuntina Sacco, M.D., Merck Sharp & Dohme LLC	Squamous Cell Carcinoma of the Head and Neck	04/25	04/26
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	Active, not recruiting	2	63	Europe, US	IO102-IO103 in combination with pembrolizumab	IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC	Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder	01/24	11/24
NCI-2018-01227, NCT03603223: Pembrolizumab in Treating Participants with Leukoplakia	Recruiting	2	26	US	Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475	Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC	Erythroleukoplakia, Leukoplakia, Verrucous Oral Leukoplakia	08/25	08/26
PEMDA-HN, NCT05814666: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC	Recruiting	2	81	Europe, US, RoW	Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda	Flamingo Therapeutics NV	HNSCC	05/25	05/26
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Withdrawn	2	130	Europe, US, RoW	RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab	Replimune Inc., Bristol-Myers Squibb	Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	03/26	06/26
NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies	Completed	1/2	40	US	IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy	ImmuneSensor Therapeutics Inc.	Solid Tumor, Adult	09/23	09/23